Immunosuppression Minimization Trials in Liver Transplantation: Can We Predict Humoral Response to Assess Eligibility?

Magdalena Meszaros; Jose Ursic-Bedoya; Stéphanie Faure; Georges-Philippe Pageaux

doi:10.1002/hep.30345

Immunosuppression Minimization Trials in Liver Transplantation: Can We Predict Humoral Response to Assess Eligibility?

Hepatology. 2019 May;69(5):2302-2303. doi: 10.1002/hep.30345.

Authors

Magdalena Meszaros¹, Jose Ursic-Bedoya¹, Stéphanie Faure¹, Georges-Philippe Pageaux¹

Affiliation

¹ CHU Saint Eloi, Département d'hépatologie et transplantation hépatique, Montpellier, France.

PMID: 30394549
DOI: 10.1002/hep.30345

Abstract

We have read with great interest the article by Jucaud et al. (1) reporting that de novo donor-specific HLA antibodies (dnDSA) development during immunosuppression (IS) withdrawal in liver transplantation (LT) was associated with acute rejection and prevented further attempts of IS withdrawal. This article is protected by copyright. All rights reserved.

Publication types

Letter
Comment

MeSH terms

Adult
Graft Rejection
Graft Survival
Humans
Liver Transplantation*
Prevalence
Retrospective Studies
Tissue Donors